Lupin Ltd receives FDA approval for Fluoxetine Tablets USP

Pharma major Lupin Limited (Lupin) has received approval for its Fluoxetine Tablets USP, 10 mg and 20 mg, from the United States Food and Drug Administration (FDA) to market a generic version of Eli Lilly and Company's (Eli Lilly) Prozac Tablets, 10 mg and 20 mg.

Lupin's Fluoxetine Tablets USP, 10 mg and 20 mg, is the generic version of Eli Lilly's Prozac Tablets, 10 mg and 20 mg. It is indicated in the treatment of:

- Major Depressive Disorder (MDD)

Fluoxetine is indicated for the acute and maintenance treatment of Maj or Depressive Disorder in adult patients and in pediatric patients aged 8 to 18 years

- Obsessive Compulsive Disorder (OCD)

Fluoxetine is indicated for the acute and maintenance treatment of obsessions and compulsions in adult patients and in pediatric patients aged 7 to 17 years with Obsessive Compulsive Disorder (OCD)

- Bulimia Nervosa

Fluoxetine is indicated for the acute and maintenance treatment of binge-eating and vomiting behaviors in adult patients with moderate to severe Bulimia Nervosa.

- Panic Disorder

Fluoxetine is indicated for the acute treatment of Panic Disorder, with or without agoraphobia, in adult patients.

Fluoxetine Tablets, 10 mg and 20 mg, (RLD: Prozac) had annual sales of approximately USD 68.2 million in the US (IQVIA MAT December 2018).

Shares of LUPIN LTD. was last trading in BSE at Rs.830.2 as compared to the previous close of Rs. 829.8. The total number of shares traded during the day was 60343 in over 1712 trades.

The stock hit an intraday high of Rs. 834.1 and intraday low of 825. The net turnover during the day was Rs. 49986567.

Source : Equity Bulls

Keywords